14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In a...
16:49 , Jun 28, 2018 |  BC Extra  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
19:55 , Apr 26, 2017 |  BC Extra  |  Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...
21:21 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

ASN100: Ph II started

Arsanis began a double-blind, placebo-controlled, international Phase II trial to evaluate a single dose of IV ASN100 in about 350 high-risk, mechanically ventilated patients. ASN100 was discovered under a deal with Adimab, which is using...
08:00 , Feb 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: α-hemolysin (aHL) Patent application filed; unavailable for licensing

Infectious disease INDICATION: Bacterial infection In vitro and mouse studies suggest a mAb against multiple Staphylococcus aureus hemolysin and leukocidin toxins could help treat bacterial infection. A yeast display screen of human antibodies identified a mAb that...
08:00 , Feb 12, 2015 |  BC Innovations  |  Targets & Mechanisms

High five for Arsanis

Researchers at Arsanis Inc. and Adimab LLC have identified an antibody that simultaneously neutralizes five Staphylococcus aureus toxins - defying the odds of hitting such diverse structures by fishing out an exposed conserved patch. While...
07:00 , Sep 29, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus Panton-Valentine leukocidin (LukS-PV; pv); Panton-Valentine leukocidin chain F precursor (LukF-PV) Mouse and rabbit studies identified...
07:00 , Apr 1, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Rabbit model of Staphylococcus aureus-induced necrotizing pneumonia A rabbit model of necrotizing pneumonia could help identify new...